New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For KERX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 3, 2015
12:23 EDTKERXOn The Fly: Top stock stories at midday
Subscribe for More Information
08:15 EDTKERXChimerix rallies, Keryx falls after Citi expands Biotech coverage
Subscribe for More Information
06:39 EDTKERXKeryx initiated with a Sell, $1.50 price target at Citi
Citi analyst Yigal Nochomovitz started shares of Keryx Biopharmaceuticals (KERX) with a Sell rating and $1.50 price target. The stock closed yesterday up 18c to $6.03. Nochomovitz expects the Auryxia launch and long-term sales trends to "materially underperform" consensus expectations. Auryxia is a phosphate binder used for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis. Nochomovitz estimates Auryxia has peak U.S. sales potential of $57M, well below the consensus estimate of $485M. He named Chimerix (CMRX) his top pick in the small- and mid-cap biotech space. The analyst initiated the name this morning with a Buy rating and $80 price target.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use